Medicine:BriLife

From HandWiki
Short description: Vaccine candidate against COVID-19
BriLife
Reuven Rivlin and the first person to receive the BriLife vaccine look at the viewer alongside two nurses. The flag of Israel sits in the background.
The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
Target diseaseSARS-CoV-2
Typeviral
Clinical data
Other namesBrilife
Routes of
administration		Intramuscular
ATC code
  • None

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]

References

  1. ↑ 1.0 1.1 "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics 11 (4): 1690–1702. 2021-01-01. doi:10.7150/thno.53691. PMID 33408775. 
  2. ↑ "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences 8: 635337. 2021. doi:10.3389/fmolb.2021.635337. PMID 33937326. 
  3. ↑ 3.0 3.1 "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews 170: 113–141. March 2021. doi:10.1016/j.addr.2021.01.003. PMID 33422546. 
  4. ↑ "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences 8: 637378. 2021-06-09. doi:10.3389/fmolb.2021.637378. PMID 34179072. 
  5. ↑ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
  6. ↑ "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases 104: 441–451. March 2021. doi:10.1016/j.ijid.2021.01.035. PMID 33476760. 
  7. ↑ "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. 12 July 2021. https://www.reuters.com/world/middle-east/israel-says-signed-mou-with-nrx-pharmaceuticals-covid-vaccine-trials-2021-07-12/. 
  8. ↑ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. https://www.i24news.tv/en/news/coronavirus/1629033834-israeli-produced-vaccine-shipped-to-georgia-for-phase-ii-trial. 
  9. ↑ "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications 11 (1): 6402. December 2020. doi:10.1038/s41467-020-20228-7. PMID 33328475. 

External links




Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:BriLife&oldid=3669113"